These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 20492573)
41. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. Kaasa S; Moksnes K; Nolte T; Lefebvre-Kuntz D; Popper L; Kress HG J Opioid Manag; 2010; 6(1):17-26. PubMed ID: 20297611 [TBL] [Abstract][Full Text] [Related]
42. Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG Clin Drug Investig; 2007; 27(9):605-11. PubMed ID: 17705569 [TBL] [Abstract][Full Text] [Related]
43. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care. Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648 [TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of fentanyl following intravenous and transdermal administration in horses. Maxwell LK; Thomasy SM; Slovis N; Kollias-Baker C Equine Vet J; 2003 Jul; 35(5):484-90. PubMed ID: 12875327 [TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Fisher A; Watling M; Smith A; Knight A Int J Clin Pharmacol Ther; 2010 Feb; 48(2):138-45. PubMed ID: 20137766 [TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers. Zecca E; Manzoni A; Centurioni F; Farina A; Bonizzoni E; Seiler D; Perrone T; Caraceni A Br J Clin Pharmacol; 2015 Jul; 80(1):110-5. PubMed ID: 25612845 [TBL] [Abstract][Full Text] [Related]
47. Fentanyl effervescent buccal tablets: new formulation. For cancer patients with breakthrough pain: a second buccal formulation with minimal evaluation. Prescrire Int; 2009 Oct; 18(103):205. PubMed ID: 19882786 [TBL] [Abstract][Full Text] [Related]
48. Assessment of the relative potency of fentanyl buccal tablet to intravenous morphine in healthy volunteers using a thermally induced hyperalgesia pain model. Saunders DL; Messina J; Darwish M; Xie F; Leary KJ; Cantilena LR J Clin Pharmacol; 2012 Jun; 52(6):870-9. PubMed ID: 21646442 [TBL] [Abstract][Full Text] [Related]
49. A phase I pharmacokinetic and bioavailability study of a sublingual fentanyl wafer in healthy volunteers. Lim CB; Schug SA; Sunderland VB; Paech MJ; Liu Y Anesth Analg; 2012 Sep; 115(3):554-9. PubMed ID: 22584544 [TBL] [Abstract][Full Text] [Related]
50. Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. Solassol I; Bressolle F; Caumette L; Garcia F; Poujol S; Culine S; Pinguet F Ther Drug Monit; 2005 Aug; 27(4):491-8. PubMed ID: 16044107 [TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics and safety of fentanyl sublingual spray and fentanyl citrate intravenous: a multiple ascending dose study in opioid-naïve healthy volunteers. Rauck RL; Oh DA; Singla N; Koch C; Parikh N; Nalamachu S; Wilson D; Yu J; Vetticaden S Curr Med Res Opin; 2017 Nov; 33(11):1921-1933. PubMed ID: 28942715 [TBL] [Abstract][Full Text] [Related]
52. Fentanyl buccal tablet: rapid relief from breakthrough pain. Taylor DR Expert Opin Pharmacother; 2007 Dec; 8(17):3043-51. PubMed ID: 18001263 [TBL] [Abstract][Full Text] [Related]
53. Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. Darwish M; Kirby M; Robertson P; Hellriegel E; Jiang JG J Clin Pharmacol; 2007 Jan; 47(1):56-63. PubMed ID: 17192502 [TBL] [Abstract][Full Text] [Related]
55. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Rauck R; North J; Gever LN; Tagarro I; Finn AL Ann Oncol; 2010 Jun; 21(6):1308-1314. PubMed ID: 19940014 [TBL] [Abstract][Full Text] [Related]
56. The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia. Wheeler M; Birmingham PK; Lugo RA; Heffner CL; Coté CJ Anesth Analg; 2004 Nov; 99(5):1347-1351. PubMed ID: 15502029 [TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics and safety of fentanyl sublingual spray and fentanyl citrate intravenous: a single ascending dose study in opioid-naïve healthy volunteers. Rauck R; Oh DA; Parikh N; Koch C; Singla N; Yu J; Nalamachu S; Vetticaden S Curr Med Res Opin; 2017 Nov; 33(11):1915-1920. PubMed ID: 28681626 [TBL] [Abstract][Full Text] [Related]
58. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. Mercadante S; Ferrera P; Adile C; Casuccio A J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977 [TBL] [Abstract][Full Text] [Related]
59. Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain. Passik SD; Narayana A; Yang R Pain Med; 2014 Aug; 15(8):1365-72. PubMed ID: 24666664 [TBL] [Abstract][Full Text] [Related]
60. Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study. Nave R; Connolly SM; Popper L; Lahu G; Schmitt H Int J Clin Pharmacol Ther; 2012 Oct; 50(10):751-9. PubMed ID: 22943926 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]